AVAIL MEDICAL PRODUCTS, INC., Device Modification – Special 510(k), Steri-Lub™ Lubrication Gel

SECTION 5: 510(k) Summary

Avail Medical Products, Inc.

1900 Carnegie Avenue

Santa Ana, CA 92705

Contact:

Submitter:

Hanumantha Hari

949-263-5060 ext. 267

NOV 2 1 2008

K487189

Name of Device:

Steri-LubTM Lubrication Gel

Predicate Device:

Steri-LubTM Lubrication Gel, K944969

Description of the New Device: The Steri-Lub™ Lubrication Gel is a sterile, single patient use, disposable instrument that is substantially equivalent to the predicate device and other pre-filled syringes. All Steri-Lub™ Lubrication Gel syringes are designed for lubrication of a body orifice to facilitate entry of a diagnostic or therapeutic device only and are intended for single patient use.

INTENDED USE OF THE NEW DEVICE: The Steri-Lub™ Lubrication Gel is intended to be used in procedures requiring a sterile product (surgical, urological). The Lubrication Gel is intended to be used to lubricate a body orifice to facilitate entry of a diagnostic or therapeutic device.

Comparison of the Technological Features of the New [Modified] Device and Predicate Devices: The modified device and the lawfully marketed predicate device contain similar materials of construction.

Signed,

Hanumantha Hari

Vice President Quality and Regulatory Affairs

Avail Medical Products, Inc.

CONFIDENTIAL Page 28 of 44



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Patricia Anne Goeree Regulatory Affairs Specialist Avail Medical Products, Incorporated 1900 Carnegie Avenue Santa Ana, California 92705

NOV 2 1 2008

Re: K083189

Trade/Device Name: Steri-Lub™ Lubrication Gel

Regulation Number: 21 CFR 880.6375 Regulation Name: Patient Lubricant

Regulatory Class: I Product Code: KMJ Dated: October 28, 2008 Received: October 30, 2008

Dear Ms. Gocree:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Chiu S. Lin, Ph. D Division Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

5 IO(K) Number (I	r known):				
Device Name:	_Steri-Lub TM	Lubricating Gel			
Indications For U	se:			·	
product (surgical	and urological).	intended to be used The Lubrication G f a diagnostic or the	el is intended to	be used to l	terile ubricate
		·			
		1		· .	
Prescription Use (Part 21 CFR 801 Su		AND/OR	Over-The-Cou (21 CFR 801 St		
(PLEASE DO N NEEDED)	OT WRITE BEL	OW THIS LINE-CO	ONTINUE ON A	NOTHER PA	AGE IF
					<u>.</u> ,
Co	ncurrence of C	DRH, Office of Dev	rice Evaluation ((ODE)	
	ave &		- 		
Ďiv	ivision Sign-Off) vision of Anesthesi ection Control, Der	ology, General Hospital Ital Devices		Page 1 of _1	
	0(k) Number: <u>k</u>	•			